Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2014-04-08 | John G. Cox (2) 51 Director; Member of the Audit Committee; Director Compensation Table for the Fiscal Year Ended December 31, 2013: John G. Cox Fees Earned or Paid in Cash $5,000, Option Awards $160,954, Total $165,954. |
| 2015-04-17 | John G. Cox has served as a director of Repligen since November 2013. Mr. Cox is currently Executive Vice President of Pharmaceutical Operations & Technology at Biogen Inc. ... Mr. Cox's qualifications to sit on the Company's Board of Directors include his extensive experience of biopharmaceutical manufacturing. ... The Audit Committee was established in accordance with section 3(a)(58)(A) of the Exchange Act and currently consists of Messrs. Ryan and Cox and Dr. Cooper. ... Director Compensation Table for the Fiscal Year Ended December 31, 2014 ... John G. Cox 42,500 Fees Earned or Paid in Cash ($) Total 42,500 |
| 2016-04-11 | John G. Cox has served as a director of Repligen since November 2013. Mr. Cox is currently Executive Vice President of Pharmaceutical Operations & Technology at Biogen Inc. ... Mr. Cox's qualifications to sit on the Company's Board of Directors include his extensive experience of biopharmaceutical manufacturing. ... The Audit Committee was established in accordance with section 3(a)(58)(A) of the Exchange Act and currently consists of Messrs. Ryan, Cox and Muir (effective as of October 2015). ... The Audit Committee met six times during the fiscal year ended December 31, 2015. ... Director Compensation Table for the Fiscal Year Ended December 31, 2015 ... John G. Cox Fees Earned or Paid in Cash($) 55,000, Stock Awards($) 76,531, Option Awards($) 81,696, Total($) 213,227. |
| 2017-04-21 | John G. Cox has served as a director of Repligen since November 2013. ... Mr. Cox's qualifications to sit on the Company's Board of Directors include his extensive experience of biopharmaceutical manufacturing. ... The Audit Committee currently consists of Mr. Muir, Chairperson, Mr. Cox and Mr. Ryan. ... Director Compensation Table for the Fiscal Year Ended December 31, 2016 ... John G. Cox 55,000 46,050 46,476 147,526 |
| 2018-04-20 | John G. Cox has served as a director of Repligen since November 2013. Mr. Cox is currently the CEO of Bioverativ Inc., a company which spun out of Biogen, Inc. in 2017, was publicly traded and was then acquired by Sanofi. ... Mr. Cox's qualifications to sit on the Company's Board of Directors include his extensive experience of biopharmaceutical manufacturing. |
| 2019-04-18 | John G. Cox has served as a director of Repligen since November 2013. ... Mr. Cox currently serves as Executive Chairman at Torque Therapeutics. ... Mr. Cox is a member of the Audit Committee. ... Director Compensation Table for the Fiscal Year Ended December 31, 2018: John G. Cox Total Compensation: $185,370. |
Data sourced from SEC filings. Last updated: 2025-10-12